Novartis Ag

Portola Pharmaceuticals, Inc.

Nicole Bieri

Murat Acemoglu

Ulrich Meier

Hans Stettler

Rita Ramos

Jörg Brozio

Dietmar Flubacher

Andreas Kordikowski

Julien Taillemite

Rasmus Mose

Maria Caterina Testa

Frank Schaefer

Vijay Sethuraman

Pascal Michel

Philipp Lustenberger

Bin Li

Tanja Meister

Sisi Zhang

Marie-Pierre Filliot

Dieter Becker

Joerg Brozio

Jorg Brozio

This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ('hydrates'). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.

Crystalline forms of a TLR7/TLR8 inhibitor

The invention discloses improved processes for manufacturing a compound, 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine, its monohydrochloride salt and intermediates thereof.

Process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine

The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Yinhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof. 

Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof

Growing community of inventors

Muttenz, Switzerland

Nicole Bieri